Company Overview and News
Another day another dollar. The market keeps going back and forth and there are certainly some good deals out there. Laurentian Bank of Canada (OTCPK:LRCDF) has really pulled back the last couple of months. I keep debating jumping into them. Seems like a good entry point currently. If I had some USD, there would be lots of choices at the moment. Lots of you are grabbing PepsiCo (NYSE:PEP), Johnson & Johnson (NYSE:JNJ) and 3M (NYSE:MMM), all solid stocks.
JNJ LB TU MMM
As the earnings season comes to a close, only five Canadian Dividend All-Stars are scheduled to report this week. Of which, only one is expected to announce a dividend increase. First, let’s see how the banks fared last week.
BMO LRCDF NA ADWPF BMO LB NTIOF
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
June 1 (Reuters) - Canada’s main stock index edged higher on Friday as gains in shares of energy companies more than offset losses in the heavyweight financials index.
SRHIF NGD NGDAF BCB DRGDF NGD NMKEF SU RNX RNX.WT COT RNKLF DGC NMX LB SU
May 30 (Reuters) - Stock futures pointed to a higher opening for Canada’s main stock index on Wednesday as Brent crude prices rose towards $76 a barrel, supported by tight supplies.
CP CP LB
MONTRÉAL, 29 mai 2018 (GLOBE NEWSWIRE) -- Banque Laurentienne Groupe Financier (la « Banque ») (TSX:LB) annonce qu’elle a résolu avec succès la situation en lien avec les prêts hypothécaires achetés par le tiers acheteur et qu’elle a conclu une entente avec la SCHL sur un plan d’action clair visant la résolution de la situation liée au programme de titrisation de la SCHL.
MONTREAL, May 29, 2018 (GLOBE NEWSWIRE) -- Laurentian Bank Financial Group (the “Bank”) (TSX:LB) announces that it has successfully resolved the identified issues related to mortgage loans purchased by the Third-Party Purchaser (“TPP”) and has agreed with CMHC on a clear action plan towards resolution on the CMHC securitization program.
MONTRÉAL, 22 mai 2018 (GLOBE NEWSWIRE) -- Banque Laurentienne Groupe Financier (TSX:LB) annonce que la divulgation et l’appel conférence de ses résultats financiers du deuxième trimestre de l’exercice 2018 prévus à l’origine le mercredi 30 mai 2018 auront maintenant lieu le vendredi 1er juin 2018. L’appel conférence aura lieu à 11 h 00.
MONTREAL, May 22, 2018 (GLOBE NEWSWIRE) -- Laurentian Bank Financial Group (TSX:LB) announces that the disclosure and conference call of its second quarter 2018 financial results originally scheduled for Wednesday, May 30, 2018, will now be held on Friday, June 1, 2018. The conference call will take place at 11:00 a.m.
21h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to TSX:LB / Laurentian Bank on message board site Silicon Investor.